NPI-001 shows more than 50% reduction in photoreceptor loss caused by RP associated with USH over two years NPI-001 was well tolerated, with no persiste...
Global pharma major Lupin Limited announced that it has received approval from the United States Food and Drug Administration (U.S. FDA) for its Ab...
The founder and long-standing CEO of PlasmidFactory GmbH, Dr. Martin Schleef, was honored in Düsseldorf with the Innovation Award 2025 of the State ...
Scipher Medicine, a pioneer in network-based and AI-driven precision immunology, announced a strategic collaboration with Maxymune Therapeutics, a ...
Collaboration will help reduce stable cell line development timelines in AAV genomic medicine development and ultimately also shorten development timeline ...
Partnership delivers advanced reverse transcriptase technology to enhance sensitivity, robustness and reproducibility of molecular analysis in clinical, ap...
Booking Health, a global medical travel platform, announced the expansion of patient access to dendritic cell immunotherapy for recurrent glioblastoma, f...
Governor Phil Murphy officially inaugurated the state-of-the-art biomanufacturing facility of Enzene, a leading global continuously innovative deve...
NurExone Biologic Inc. , a pioneering biopharmaceutical company developing exosome-based regenerative therapies, is pleased to announce that the United S...
Daiichi Sankyo (TSE: 4568) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced positive results from the Phase 2...
New Jersey at a Glance – Often dubbed the “Medicine Chest of the World,” New Jersey has a rich legacy and a dynamic present as a global h...
MEDIPAL HOLDINGS CORPORATION (TSE 7459, MEDIPAL) and JCR Pharmaceuticals Co., Ltd. (TSE 4552, JCR) announced that the two companies have signed an exclus...
Highly Complementary Technologies Strengthen Thermo Fisher’s Portfolio in Bioprocessing and Adjacent Markets Thermo Fisher Scientific Inc. , the w...
Phase III trial informed by comprehensive KARDIA data set generated through three Phase II studies: KARDIA-1, KARDIA-2 and KARDIA-3 In the Phase II KA...
© 2025 Biopharma Boardroom. All Rights Reserved.
